215 results
8-K
EX-99.1
KA
Kineta Inc
8 Apr 24
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
4:02pm
, marketing and manufacturing capabilities and strategy; developments and projections relating to Kineta’s competitors and its industry; the impact
8-K
EX-99.1
KA
Kineta Inc
21 Mar 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4:04pm
acceptance of Kineta’s product candidates; Kineta’s commercialization, marketing and manufacturing capabilities and strategy; developments
8-K
KA
Kineta Inc
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
and manufacturing capabilities and strategy; developments and projections relating to Kineta’s competitors and its industry; the impact of government laws
8-K
EX-99.1
fh0lbo
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
8-K
EX-99.2
4qy1a8
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
8-K
EX-99.1
7m4a gzsviy
17 Jan 24
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
8:30am
8-K
EX-99.1
3t6 48x9d3kd3v7gu
5 Jan 24
Regulation FD Disclosure
4:30pm
424B3
4q8wywf17xm2wqby uu
13 Nov 23
Prospectus supplement
5:28pm
8-K
EX-99.2
j0aod n7qcy
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
EX-99.1
o3fa3ssd8ekj2t
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
EX-99.1
bm0w24do3dlc4inix wo
3 Nov 23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:02pm
8-K
EX-99.1
c8579
3 Nov 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
4:01pm
8-K
EX-99.2
2orm3q5spf
17 Oct 23
Entry into a Material Definitive Agreement
8:32am
8-K
EX-99.1
f8okytwg21 tgbob9jx5
17 Oct 23
Entry into a Material Definitive Agreement
8:32am
8-K
EX-99.1
908lz8f761kzdxl
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
424B5
bi5kymyq7wijra 8ro8i
5 Oct 23
Prospectus supplement for primary offering
10:47am